<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(4)</volume><submitter>Stone GW</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Reshaping the dilated left ventricle using a surgically implanted papillary muscle sling has been shown to provide long-term improvement in cardiac function compared to annuloplasty alone in patients with systolic heart failure. A papillary muscle sling which can be implanted via a transcatheter approach has the potential to make this treatment more widely available to patients.&lt;h4>Methods&lt;/h4>The Vsling transcatheter papillary muscle sling device was evaluated in a chronic animal model (sacrificed at 30 and 90 days), in a simulator, and in a human cadaver.&lt;h4>Results&lt;/h4>The Vsling device was successfully implanted in 10 pigs, 6 simulator procedures, and 1 human cadaver. Procedure complexity and device usability were rated as reasonable or better by 6 interventional car</pubmed_abstract><journal>Structural heart : the journal of the Heart Team</journal><pagination>100075</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10242562</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Description, Feasibility, and Histological Assessment of the Vsling, a Novel Transcatheter Ventricular Repair Device.</pubmed_title><pmcid>PMC10242562</pmcid><pubmed_authors>Stone GW</pubmed_authors><pubmed_authors>Manash B</pubmed_authors><pubmed_authors>Neustadter D</pubmed_authors><pubmed_authors>Sievert H</pubmed_authors><pubmed_authors>Virmani R</pubmed_authors><pubmed_authors>Shaler LW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Description, Feasibility, and Histological Assessment of the Vsling, a Novel Transcatheter Ventricular Repair Device.</name><description>&lt;h4>Background&lt;/h4>Reshaping the dilated left ventricle using a surgically implanted papillary muscle sling has been shown to provide long-term improvement in cardiac function compared to annuloplasty alone in patients with systolic heart failure. A papillary muscle sling which can be implanted via a transcatheter approach has the potential to make this treatment more widely available to patients.&lt;h4>Methods&lt;/h4>The Vsling transcatheter papillary muscle sling device was evaluated in a chronic animal model (sacrificed at 30 and 90 days), in a simulator, and in a human cadaver.&lt;h4>Results&lt;/h4>The Vsling device was successfully implanted in 10 pigs, 6 simulator procedures, and 1 human cadaver. Procedure complexity and device usability were rated as reasonable or better by 6 interventional car</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-19T07:21:16.085Z</modification><creation>2024-12-04T08:14:13.203Z</creation></dates><accession>S-EPMC10242562</accession><cross_references><pubmed>37288331</pubmed><doi>10.1016/j.shj.2022.100075</doi></cross_references></HashMap>